Facebook Linkedin Twitter
Inside Precision Medicine Stakeholders Urge CMS to Revise NCD Interpretation for NGS Tests

Ovarian cancer

More than 60 healthcare stakeholders have signed a letter urging the Centers for Medicare and Medicaid Services (CMS) to revise its interpretation of the National Coverage Determination (NCD) for Next Generation Sequencing (NGS)
Molecular Dx

Stakeholders Urge CMS to Revise NCD Interpretation for NGS Tests

0
Georgia Tech researchers (l-r) John McDonald
News & Features

Open Source Tool Predicts Chemo Drugs Best Suited for Individual Patients

0
Personalized Oncology Roadmap for Oncologists
News & Features

Personalized Oncology Roadmap for Oncologists

0
Doctors attending patients receiving intravenous infusion in hospital
News & Features

UCSF Researchers Release Gene-Drug Interaction Map for Precision Chemotherapy

0
Patient having a mouth swab test
Molecular Dx

FDA Authorizes First DTC Cancer Risk Test, 23andMe’s GRH Report for BRCA1 and BRCA2 Mutations

0
Micrograph of ovarian dysgerminoma
Molecular Dx

AZ to Use Myriad’s myChoice HRD Plus Test in Phase III Trial

0
Ironman-Boxes-PGM-Dx-30Apr2017
Molecular Dx

CMS Proposes Coverage for Thermo Fisher Scientific NSCLC Diagnostic

Alex Philippidis
0
Detection of Ovarian Cancer Recurrence: Quality Control Routines using an Integrated Proteomics Approach
News & Features

Detection of Ovarian Cancer Recurrence: Quality Control Routines using an Integrated Proteomics Approach

0
Genetics of Neurodegenerative Disorders – How Mutations Affect Disease Pathology
News & Features

Genetics of Neurodegenerative Disorders – How Mutations Affect Disease Pathology

0
Two Young Women at a Breast Cancer Awareness Rally
News & Features

Racial Disparities of Cancer-Causing Mutations Addressed in New Study

0
1...8910Page 9 of 10

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine